Thera-SAbDab

PROLGOLIMAB

>   Structural Summary
TherapeuticProlgolimab
TargetPDCD1/CD279/PD1
Heavy ChainQVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS
Light ChainQPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technology
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedBiocad
Conditions ApprovedMalignant melanoma
Conditions ActiveCervical cancer, Non-small cell lung cancer, Hodgkin's disease
Conditions DiscontinuedSolid tumours
NotesGenetics: vicpac/homosap

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy